DUALAGO
DEAD

Serial Number

98472298

Owner

BRISTOL-MYERS SQUIBB COMPANY

Attorney

Marilyn F. Kelly

Filing Date

Mar 28, 2024

Add to watchlist:

No watchlists yet
View on USPTO

DUALAGO Trademark

Serial Number: 98472298

DUALAGO is a trademark filed by BRISTOL-MYERS SQUIBB COMPANY on March 28, 2024. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

BRISTOL-MYERS SQUIBB COMPANY (4,762 trademarks)

NEW YORK, NY 10154

Entity Type: 03

Trademark Details

Filing Date

March 28, 2024

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; pharmaceutical preparations for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations; diagnostic agents, preparations and substances for medical purposes; radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer; radio-isotope markers for therapeutic or diagnostic use.

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Apr 14, 2025 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Apr 14, 2025 ABN2
NOTIFICATION OF FINAL REFUSAL EMAILED
Dec 27, 2024 GNFN
FINAL REFUSAL E-MAILED
Dec 27, 2024 GNFR
FINAL REFUSAL WRITTEN
Dec 27, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 1, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 1, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 1, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 7, 2024 GNRN
NON-FINAL ACTION E-MAILED
Aug 7, 2024 GNRT
NON-FINAL ACTION WRITTEN
Aug 7, 2024 CNRT
ASSIGNED TO EXAMINER
Aug 6, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 2, 2024 NWOS
NEW APPLICATION ENTERED
Mar 28, 2024 NWAP